Abstract
A growing body of research describes cancers other than breast and ovarian in families with BRCA1/2 mutations, but the prevalence and characteristics of pancreatic cancer in these families has not been well described. This study was designed to: (1) estimate the prevalence of pancreatic cancer in BRCA1/2 positive families; (2) ascertain age of onset and gender distribution of pancreatic cancer in this cohort; and (3) compare age and gender characteristics of pancreatic cancer in BRCA1/2 positive families with those of the general population. Within the UCSF Cancer Risk Program cohort, 24/219 (11.0%) BRCA1 and 17/156 (10.9%) BRCA2 families had at least 1 individual with pancreatic cancer. In the 24 BRCA1 families, median age of diagnosis was 59 (range 45–80) in males, and 68 (range 38–87) in females (male:female ratio = 2.00). In the 17 BRCA2 families, median age of diagnosis was 67 (range 39–78) in males and 59 (range 46–81) in females (male:female ratio = 1.11). The SEER database, which describes cancer characteristics in a representative sample of the US population, reports a median age of 70 in males and 74 in females (male:female ratio = 0.96) over the same time period. Additionally, mean ages of diagnosis of pancreatic cancer in BRCA1/2 families differ significantly from the SEER mean (P = 0.0014 for BRCA1 and P = 0.011 for BRCA2 by unpaired t-test). Our findings suggest that families with early onset pancreatic cancer and features of hereditary breast and ovarian cancer should be considered for BRCA1/2 testing.
Similar content being viewed by others
Abbreviations
- SEER:
-
Surveillance Epidemiology and End Results
References
Lichtenstein P, Holm NV, Verkasalo PK et al (2000) Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343(2):78–85. doi:10.1056/NEJM200007133430201
King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643–646. doi:10.1126/science.1088759
Antoniou AC, Pharoah PD, Narod S et al (2005) Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 42(7):602–603. doi:10.1136/jmg.2004.024133
Thompson D, Easton DF, Breast Cancer Linkage Consortium (2002) Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94(18):1358–1365
The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91(15):1310–1316. doi:10.1093/jnci/91.15.1310
van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON) et al (2005) Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 42(9):711–719. doi:10.1136/jmg.2004.028829
Goggins M, Schutte M, Lu J et al (1996) Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56(23):5360–5364
Lynch HT, Deters CA, Snyder CL et al (2005) BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet Cytogenet 158(2):119–125. doi:10.1016/j.cancergencyto.2004.01.032
Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22(4):735–742. doi:10.1200/JCO.2004.05.055
Offit K, Levran O, Mullaney B et al (2003) Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 95(20):1548–1551
Lee R, Beattie M, Crawford B et al (2005) Recruitment, genetic counseling, and BRCA testing for underserved women at a public hospital. Genet Test 9(4):306–312
Berry DA, Iversen ES Jr, Gudbjartsson DF et al (2002) BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20(11):2701–2712. doi:10.1200/JCO.2002.05.121
Ries LAG, Melbert D, Krapcho M et al (2007) SEER cancer statistics review, 1975–2004. National Cancer Institute, Bethesda, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site
Petersen GM, de Andrade M, Goggins M et al (2006) Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev 15(4):704–710. doi:10.1158/1055-9965.EPI-05-0734
Greer JB, Whitcomb DC (2007) Role of BRCA1 and BRCA2 mutations in pancreatic cancer. Gut 56(5):601–605. doi:10.1136/gut.2006.101220
Tonin P, Weber B, Offit K et al (1996) Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 2(11):1179–1183. doi:10.1038/nm1196-1179
Evans DG, Howell A (2004) Are BRCA1- and BRCA2-related breast cancers associated with increased mortality? Breast Cancer Res 6(1):E7. doi:10.1186/bcr748
Robson ME, Chappuis PO, Satagopan J et al (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6(1):R8–R17. doi:10.1186/bcr658
Robles-Díaz L, Goldfrank DJ, Kauff ND et al (2004) Hereditary ovarian cancer in Ashkenazi Jews. Fam Cancer 3(3–4):259–264. doi:10.1007/s10689-004-9552-0
Whittemore AS, Gong G, John EM (2004) Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. Cancer Epidemiol Biomarkers Prev 13(12):2078–2083
Bermejo-Pérez MJ, Márquez-Calderón S, Llanos-Méndez A (2007) Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer 121(2):225–231. doi:10.1002/ijc.22817
Canto MI, Goggins M, Hruban RH et al (2006) Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 4(6):766–781. doi:10.1016/j.cgh.2006.02.005
Chenevix-Trench G, Healey S, Lakhani S et al (2006) Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 66(4):2019–2027. doi:10.1158/0008-5472.CAN-05-3546
Ozcelik H, Schmocker B, Di Nicola N et al (1997) Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 16(1):17–18. doi:10.1038/ng0597-17
Acknowledgments
This publication was supported by NIH/NCRR/OD UCSF-CTSI Grant Number KL2 RR024130. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, D.H., Crawford, B., Ziegler, J. et al. Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations. Familial Cancer 8, 153–158 (2009). https://doi.org/10.1007/s10689-008-9220-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10689-008-9220-x